Citations

Clear

2960 citation(s) found for "Kim, P".

The effect of intravenous thrombolysis in stroke patients with unsuccessful thrombectomy
Elawady, Sameh Samir , Kasem, Rahim Abo , Sowlat, Mohamed Mahdi, Nawabi, Noah, Venegas, Joshua M. , Isidor, Julio , Loulida, Hasna , Maier, Ilko , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Kan, Peter, Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kasab, Sami Al , Venegas, Joshua M , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Altschul, David J , Crosa, Roberto , Abo Kasem, Rahim , Matsukawa, Hidetoshi , Cunningham, Conor M. , Orscelik, Atakan , Jabbour, Pascal , Rai, Ansaar , Samaniego, Edgar A , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Matouk, Charles , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De

Mayo Clinic

Interventional Neuroradiology | September 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241279009 | PMID 39262342 Get It

Background The benefit of intravenous thrombolysis (IVT) is well established. We aim to study the benefits of IVT in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) who underwent unsuccessful mechanical thrombectomy (MT). Methods We included AIS patients who underwent MT for anterior circulation LVO with failed recanalization (modified treatment in cerebral ischemia [mTICI] score ≤ 2A). Patients who received IVT prior to MT were compared to those who received MT alone. Propensity score matching using demographic, clinical, radiographic and procedural variables was used to match patients with and without IVT. The primary outcome was favorable 90-day good functional outcome (defined as modified Rankin scale of 0–2), and secondary outcomes included intracranial hemorrhage (ICH), symptomatic ICH (sICH), and 90-day mortality. Results Totally, 610 AIS patients with unsuccessful MT were included. After propensity matching, 219 patients were identified in each group. Median age was 70 years and 73 years in the IVT + MT and MT alone groups, respectively. In the IVT + MT group, final mTICI scores of 0, 1, and 2A were achieved in 92 (42.0%), 33 (15.1%), and 94 (42.9%) patients, respectively, versus 76 (34.7%), 29 (13.2%), and 114 (52.1%) in the MT alone group. The IVT + MT group had greater odds of 90-day good functional outcome (adjusted odds ratio 2.54, 95% confidence interval 1.53–4.32). There were no significant differences in secondary outcomes. Conclusions IVT is associated with improved functional outcomes in AIS patients with LVO despite unsuccessful MT.
Sex differences in the epidemiology of spontaneous and traumatic cervical artery dissections
Schipani, Elke , Griffin, Kim J. , Oakley, Carlee I. , Keser, Zafer , Keser, Zafer

Mayo Clinic

Stroke and Vascular Neurology | September 12, 2024 | Volume: 10 | Issue: 3 | Pages: 407-410

10.1136/svn-2024-003282 | PMID 39266209 Get It

Background Recent studies show cervical artery dissection (CeAD) is equally common between sexes, and that the incidence of CeAD has risen at a greater rate in females than males. In this population-based study, we identify sex differences in patients diagnosed with spontaneous and traumatic CeAD. Methods 144 patients with spontaneous or traumatic CeAD were studied for sex differences in medical comorbidities, presenting symptoms and outcomes. Results Females were more likely to carry a diagnosis of migraine, while males were more likely to have hyperlipidaemia. Females were more likely to present with neck pain, males with stroke. Females were significantly more likely to develop recurrent dissections in the study period. Conclusions These findings underscore the importance of understanding CeAD through the lens of sex differences and may explain the significant rise in the diagnosis of CeAD in females. These findings support the importance of considering sex-specific risk factors and medical comorbidities with sex predilection in the diagnosis and management of CeAD. Furthermore, it emphasises the importance of female patients understanding risk factors and presenting signs that should prompt evaluation for CeAD.
Targeting Glioblastoma Tumor Hyaluronan to Enhance Therapeutic Interventions that Regulate Metabolic Cell Properties
Neves, Edward R., Anand, Achal, Mueller, Joseph, Remy, R, Pedrón, Sara , Pedrón-Haba, Sara , Mueller, Joseph, Xu, Huiyan , Selting, Kim A. , Sarkaria, Jann N. , Harley, Brendan A.C.

Mayo Clinic

Advanced Therapeutics | September 11, 2024 | Volume: 7 | Issue: 10 | Pages: No page available

10.1002/adtp.202400041 | PMID 40248278 Get It

Abstract Despite extensive advances in cancer research, glioblastoma (GBM) still remains a very locally invasive and thus challenging tumor to treat, with a poor median survival. Tumor cells remodel their microenvironment and utilize extracellular matrix to promote invasion and therapeutic resistance. It is aimed here to determine how GBM cells exploit hyaluronan (HA) to maintain proliferation using ligand‐receptor dependent and ligand‐receptor independent signaling. Tissue engineering approaches are used to recreate the 3D tumor microenvironment in vitro, then analyze shifts in metabolism, hyaluronan secretion, HA molecular weight distribution, as well as hyaluronan synthetic enzymes (HAS) and hyaluronidases (HYAL) activity in an array of patient‐derived xenograft GBM cells. It is revealed that endogenous HA plays a role in mitochondrial respiration and cell proliferation in a tumor subtype‐dependent manner. A tumor‐specific combination treatment of HYAL and HAS inhibitors is proposed to disrupt the HA stabilizing role in GBM cells. Taken together, these data shed light on the dual metabolic and ligand – dependent signaling roles of hyaluronan in glioblastoma.
Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans
Kristensen, Jonas Henrik , Hasselbalch, Rasmus Bo , Strandkjær, Nina , Jørgensen, Nicoline, Østergaard, Morten, Møller‐Sørensen, Hasse , Nilsson, Jens Christian , Kamstrup, Pia R. , Dahl, Morten , Bor, Mustafa Vakur , Rode, Line , Holmvang, Lene , Bang, Lia E., Forman, Julie Lyng , Jaffe, Allan S. , Thygesen, Kristian , Bundgaard, Henning , Iversen, Kasper , Møller-Sørensen, Peter Hasse , Afzal, Shoaib , Kamstrup, Pia Rørbæk , Dahl, Morten , Frikke-Schmidt, Ruth , Jørgensen, Niklas Rye , Rode, Line , Kjærgaard, Jesper , Forman, Julie , Dalhoff, Kim , Jaffe, Allan S. , Bundgaard, Henning , Iversen, Kasper Karmark , Jørgensen, Niklas Rye , Kjærgaard, Jesper

Mayo Clinic

Circulation | September 10, 2024 | Volume: 150 | Issue: 15 | Pages: 1187-1198

10.1161/circulationaha.123.066565 | PMID 39253802 Get It

BACKGROUND: Cardiac troponin (cTn) is key in diagnosing myocardial infarction (MI). After MI, the clinically observed half-life of cTn has been reported to be 7 to 20 hours, but this estimate reflects the combined elimination and simultaneous release of cTn from cardiomyocytes. More precise timing of myocardial injuries necessitates separation of these 2 components. We used a novel method for determination of isolated cTn elimination kinetics in humans. METHODS: Patients with MI were included within 24 hours after revascularization and underwent plasmapheresis to obtain plasma with a high cTn concentration. After at least 3 weeks, patients returned for an autologous plasma retransfusion followed by blood sampling for 8 hours. cTn was measured with 5 different high-sensitivity cTn assays. RESULTS: Of 25 included patients, 20 participants (mean age, 64.5 years; SD, 8.2 years; 4 women [20%]) received a retransfusion after a median of 5.8 weeks (interquartile range, 5.0–6.9 weeks) after MI. After retransfusion of a median of 620 mL (range, 180–679 mL) autologous plasma, the concentration of cTn in participants’ blood increased 4 to 445 times above the upper reference level of the 5 high-sensitivity cTn assays. The median elimination half-life ranged from 134.1 minutes (95% CI, 117.8–168.0) for the Elecsys high-sensitivity cTnT assay to 239.7 minutes (95% CI, 153.7–295.1) for the Vitros high-sensitivity cTnI assay. The median clearance of cTnI ranged from 40.3 mL/min (95% CI, 32.0–44.9) to 52.7 mL/min (95% CI, 42.2–57.8). The clearance of cTnT was 77.0 mL/min (95% CI, 45.2–95.0). CONCLUSIONS: This novel method showed that the elimination half-life of cTnI and cTnT was 5 to 16 hours shorter than previously reported. This indicates a considerably longer duration of cardiomyocyte cTn release after MI than previously thought. Improved knowledge of timing of myocardial injury may call for changes in the management of MI and other disorders with myocardial injury.
Shiftwork and Burnout Among Trauma Surgeons: A Preliminary Analysis of Trauma Surgeons’ Fatigue and Stress Related to Overnight Shifts
Kim, Joseph , Navarro, Sergio M. , Park, Myung S., Navarro, Sergio Michael , Kim, Joseph Y , Norasi, Hamid , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 10, 2024 | Volume: 68 | Issue: 1 | Pages: 499-503

10.1177/10711813241263812 Get It

Burnout is a challenging issue among surgeons. Many factors have been linked to burnout, such as an inadequate work-life balance, high stress levels, and the frequency of on-call, overnight shifts. There is a lack of research on factors in surgeons’ daily lives associated with burnout. This study observed trauma surgeons with daily surveys assessing stress and fatigue over 9 days (6 day shifts, three night shifts). This study analyzes surgeons’ stress and fatigue levels. The study population was compared to the population of US critical care surgeons to ensure representativeness based on age, sex, and rates of burnout. Overnight shifts showed high stress and fatigue levels relative to off days, day shifts, the 3 days before, and the 3 days after overnight shifts. Days performing surgery were also more stressful and fatiguing than non-surgery work days and off days. Fatigue and stress levels were minimized during off days.
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Prinzi, Federica Lo , Salani, Francesca , Antonuzzo, Lorenzo , Satake, Tomoyuki, Vandeputte, Hanne, Pressiani, Tiziana , Finkelmeier, Fabian , Pircher, Chiara , Braconi, Chiara , Pastorino, Alessandro , Castet, Florian , Parisi, Alessandro , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Rosa, Antonio De, Lavacchi, Daniele, Dekervel, Jeroen , Balsano, Rita , Viola, Massimo, Silvestro, Lucrezia , Boccaccino, Alessandra , Himmelsbach, Vera, Zanuso, Valentina , Rimassa, Lorenza , Casadei‐Gardini, Andrea , Lo Prinzi, Federica , Abidoye, Oluseyi , Parisi, Alessandro , Ikeda, Masafumi , Antonuzzo, Lorenzo , Casadei-Gardini, Andrea , Finkelmeier, Fabian , Castet, Florian , Adeva, Jorge , Rimassa, Lorenza , Casadei-Gardini, Andrea , Pressiani, Tiziana , Roque, Ricardo , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Rimini, Margherita , Rizzato, Mario Domenico , Camera, Silvia , Vivaldi, Caterina , Lucchetti, Jessica , Kim, Jin Won , Rapposelli, Ilario Giovanni , Tamberi, Stefano , Giordano, Guido , Chon, Hong Jae , Tamburini, Emiliano , Yoo, Changhoon , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Oneda, Ester , Verrico, Monica , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Fornaro, Lorenzo , Rossari, Federico , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Bekaii‐Saab, Tanios , Esposito, Luca , Landriscina, Matteo , Djaballah, Selma Ahcene , Masi, Gianluca , Lonardi, Sara

Mayo Clinic

The Oncologist | September 6, 2024 | Volume: 30 | Issue: 3 | Pages: No page available

10.1093/oncolo/oyae256 | PMID 39427227 Get It

Abstract Background In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our study aimed to assess if the efficacy of cisplatin-gemcitabine-durvalumab (CGD) in this population is comparable to that reported in the phase 3 trial. Methods The study cohort included patients with BTC who underwent surgery on the primary tumor, experienced disease recurrence occurring ≤6 months or >6 months after surgery or after the end of adjuvant therapy and started CGD. The primary objectives were overall survival (OS) and progression free survival (PFS). Results A total of 178 patients were enrolled. No significant differences were observed between early and late relapse groups in OS (23.4 months vs not reached; HR 1.26; 95% CI, 0.67-2.37; P = .45) and PFS [7.0 months vs 9.8 months; HR 1.3(95% CI, 0.9-2.1) P = .13]. Overall response rate and disease control rate (P = .33 and P = .62) were comparable between the 2 groups, as the overall safety profile. In addition, we compared survival outcomes between the selected population and a historical cohort of patients with BTC treated with cisplatin-gemcitabine (CG) and found that despite the absence of statistical significance, CGD showed an outcome trend compared with CG regardless of the time of recurrence after surgery or adjuvant chemotherapy [(CG ≤ 6 vs CGD ≤ 6 months: HR 0.59, 95%CI, 0.35-1.01, P = .05; HR 0.70; 95%CI, 0.46-1.06, P = .09, OS and PFS, respectively) and (CG > 6 vs. CGD > 6 months: HR 0.50; 95%CI, 0.29-0.88, P = 0.0165; HR 0.54; 95%CI, 0.35-0.84, P = .0068, OS and PFS, respectively)]. Conclusion Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Jhaveri, Komal , Lim, Elgene , Jeselsohn, Rinath , Cynthia, X. , Hamilton, Erika , Osborne, Cynthia R. , Bhave, Manali Ajay, Kaufman, Peter A. , Beck, J. Thaddeus , Manso, Luís , Parajuli, Ritesh , Wang, Hwei-Chung, Tao, Jessica J. , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean‐Yves , Lu, Yen‐Shen , Larson, Timothy , Jerez, Yolanda , Sohn, Joohyuk , Saura, Cristina , Bardia, Aditya , Sammons, Sarah , Bacchion, Francesca , Li, Yujia , Estrem, Shawn T. , Nguyen, Bastien , Ismail‐Khan, Roohi , Smyth, Lillian M. , Beeram, Muralidhar , Jhaveri, Komal L , Ma, Cynthia , Hamilton, Erika P , Manso Sanchez, Luis , Im, Seock-Ah , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean-Yves , Lu, Yen-Shen , Larson, Timothy , Sideras, Kostandinos , Sohn, Joohyuk , Kim, Sung-Bae , Saura, Cristina , Bardia, Aditya , Sammons, Sarah L , Li, Yujia , Nguyen, Bastien , Ismail-Khan, Roohi , Smyth, Lillian , Beck, Joseph T , Im, Seock‐Ah , Sideras, Kostandinos , Yuen, Eunice , Rodrik-Outmezguine, Vanessa S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2024 | Volume: 42 | Issue: 35 | Pages: 4173-4186

10.1200/jco.23.02733 | PMID 39241211 Get It

PURPOSE Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1- mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) advanced breast cancer (ABC) and endometrial endometrioid cancer. The ER+/human epidermal growth factor receptor 2–negative (HER2–) ABC experience is reported here. METHODS An i3+3 dose-escalation design was used, followed by dose expansions of imlunestrant as monotherapy or in combination with abemaciclib with or without aromatase inhibitor (AI), everolimus, or alpelisib. Imlunestrant was administered orally once daily and with the combination partner per label. RESULTS Overall, 262 patients with ER+/HER2– ABC were treated (phase Ia, n = 74; phase Ib, n = 188). Among patients who received imlunestrant monotherapy (n = 114), no dose-limiting toxicities or discontinuations occurred. At the RP2D (400 mg once daily), patients (n = 51) reported grade 1-2 nausea (39.2%), fatigue (39.2%), and diarrhea (29.4%). Patients at RP2D had received previous cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; 92.2%), fulvestrant (41.2%), and chemotherapy (29.4%) for ABC and achieved a median progression-free survival (mPFS) of 7.2 months (95% CI, 3.7 to 8.3). Among patients who received imlunestrant + abemaciclib (n = 42) and imlunestrant + abemaciclib + AI (n = 43), most (69.4%) were treatment-naïve for ABC; all were CDK4/6i-naïve. Patients treated with imlunestrant + everolimus (n = 42)/alpelisib (n = 21) had received previous CDK4/6i (100%), fulvestrant (34.9%), and chemotherapy (17.5%) for ABC. No new safety signals or interactions with partnered drugs were observed. The mPFS was 19.2 months (95% CI, 13.8 to not available) for imlunestrant + abemaciclib and was not reached for imlunestrant + abemaciclib + AI. The mPFS with imlunestrant + everolimus/alpelisib was 15.9 months (95% CI, 11.3 to 19.1)/9.2 months (95% CI, 3.7 to 11.1). Antitumor activity was evident regardless of ESR1 mutation status. CONCLUSION Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2– ABC.
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Bennett, Jeffrey L. , Pittock, Sean J. , Paul, Friedemann , Kim, Ho Jin , Irani, Sarosh R. , O'Connor, Kevin C., Patterson, Kristina R. , Gunsior, Michele , Mittereder, Nanette , Rees, William A. , Cimbora, Daniel , Pittock, S J , Cree, Bruce Ac , Bennett, Jeffrey L , Irani, Sarosh R , Paul, Friedemann , Smith, Michael A. , Cree, Bruce

Mayo Clinic

Annals of Clinical and Translational Neurology | September 2, 2024 | Volume: 11 | Issue: 10 | Pages: 2792-2798

10.1002/acn3.52171 | PMID 39222408 Get It

Abstract This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20 + and CD27 + B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit ( p = 0.016) and from baseline to attack ( p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.